- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 112 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 261 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 113 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 123 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 205 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 126 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen | |
| 18.07.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2025 | 404 | GlobeNewswire (Europe) | Strong instrument sales Quarter April-June 2025Net sales amounted to SEK 129.3 million (137.0), corresponding to a decrease of 5.6 percent. Organic sales growth amounted to -3.3 percent, currency effects... ► Artikel lesen | |
| 07.05.25 | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics | 383 | GlobeNewswire (Europe) | At the Annual General Meeting 2025 (the "AGM") it was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance... ► Artikel lesen | |
| 28.04.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2025 | 367 | GlobeNewswire (Europe) | Transformative quarter
Quarter January-March 2025Net sales amounted to SEK 112.9 million (147.8), corresponding to a decrease of 23.6 percent. Organic sales growth amounted to -25.1 percent, currency... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,370 | -1,83 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| FRESENIUS | 50,78 | -0,24 % | Dax-Konzern liefert: Fresenius legt starkes Jahresergebnis vor und erhöht die Dividende | © Foto: Arne Dedert/dpaEin starkes Schlussquartal treibt Fresenius zu soliden Jahreszahlen und höherer Dividende, doch die Aktie reagiert mit Verlusten.Der Gesundheitskonzern Fresenius hat im Geschäftsjahr... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,840 | +0,99 % | Starke Zahlen: Fresenius Medical Care beendet Gesamtjahr mit Ergebnisfeuerwerk | © Foto: Frank Rumpenhorst - dpaFresenius Medical Care legt starke Gesamtjahreszahlen vor, steigert dank Sparkurs und US-Rückenwind deutlich den Gewinn und überrascht insgesamt positiv.Der Dialysespezialist... ► Artikel lesen | |
| GENEDX | 74,20 | -6,98 % | These Analysts Slash Their Forecasts On GeneDx After Q4 Results | ||
| PROGYNY | 17,600 | 0,00 % | KeyBanc senkt Kursziel für Progyny-Aktie aufgrund konservativer Schätzungen | ||
| PROCEPT BIOROBOTICS | 25,920 | 0,00 % | PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance | SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 41,570 | +0,46 % | BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance | LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 25,800 | -4,87 % | Carl Zeiss Meditec AG: ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options | Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate - whether as a standalone cloud application or as an integrated... ► Artikel lesen | |
| GERRESHEIMER | 16,120 | -4,90 % | Gerresheimer unter Druck: UBS rät jetzt zum Verkauf | Gerresheimer gerät nach einer Herabstufung durch die UBS massiv unter Druck, die das Kursziel deutlich senkt und vor schwachen Verkaufserlösen sowie operativen Risiken warnt. Zusätzlich belasten Bilanzunregelmäßigkeiten... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,640 | +2,19 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| HEARTFLOW | 24,050 | +4,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,110 | -2,01 % | EQS-AFR: Eckert & Ziegler SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Eckert & Ziegler SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Eckert & Ziegler SE: Vorabbekanntmachung... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,020 | +1,22 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 7,430 | 0,00 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Updated Full Year 2025 and Initial Full Year 2026 Guidance | ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,150 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Fourth Quarter and Full Year 2025 Results | SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen |
BOULE DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.